VK 5211

Drug Profile

VK 5211

Alternative Names: LGD 4033; VK-5211

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Viking Therapeutics
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hip fracture
  • Preclinical Cachexia
  • No development reported Hypogonadism; Muscular atrophy; Osteoporosis

Most Recent Events

  • 01 Sep 2016 Adverse events and pharmacokinetics data from a phase I trial in Hip fracture released by Viking Therapeutics
  • 01 Sep 2016 Viking Therapeutics completes a phase I trial in Hip fracture in USA
  • 01 Sep 2016 Viking Therapeutics initiates enrolment in a phase I trial for Hip fracture in USA before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top